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ABSTRACT
Peripheral arterial disease (PAD) is a disease involving reduction of blood flow 
to the inferior extremities associated with atherosclerotic lesions. In 2010, 
more than 200 million people with PAD were reported globally, including 54.8 
million in Southeast Asia. The high prevalence of PAD causes its management 
to become challenging for clinicians. Nitric oxide (NO) has a role in endothelial 
function that is associated with the appearance of symptoms in patients 
with PAD. Exogenous nitrate is usually used as a primary vasodilator in the 
treatment of angina pectoris and Prinzmetal angina. However, information 
concerning the role of nitrate administration to improve patients with 
symptomatic PAD is limited. This study aimed to evaluate the effectiveness 
of exogenous nitrates in increasing plasma NO levels and improving patients 
with PAD. A prospective pre-post clinical trial was conducted involving 
patients with PAD who were registered in the vascular registry at Dr. Sardjito 
General Hospital, Yogyakarta. Primary endpoint was the change in plasma NO 
levels after short term administration of nitroglycerin oral 2.5 mg once daily (4 
h) and long term (7 d). Analysis of variance test with Bonferroni posttest was 
used for statistical hypothesis testing. Among 33 subjects who completed this 
study, no negative side effects, and only one hypotensive patient was reported 
at the first follow-up after 4 h of the nitroglycerin administration. Plasma NO 
levels increased in the post 4 h and in the post 7 d administration. However, 
no statistically significant difference was observed (p > 0.05). Administration 
of exogenous nitrates in patients with PAD increases the plasma NO levels, 
even though it is not statistically significant. 
ABSTRAK
Penyakit arteri perifer atau peripheral artery disease (PAD) adalah penyakit 
yang ditandai dengan penurunan aliran darah ke anggota gerak bawah 
akibat lesi aterosklerosis. Pada tahun 2010, terdapat lebih dari 200 juta 
penderita PAD dilaporkan secara global dengan 54.8 juta di antaranya di Asia 
Tenggara. Prevalensi pasien PAD yang tinggi, menjadikan manajemen pasien 
ini sebagai tantangan bagi klinisi. Nitrit oksida (NO), berperan pada fungsi 
endotel dan dihubungkan dengan timbulnya gejala pada pasien PAD. Nitrat 
eksogen biasa digunakan sebagai vasodilator primer pada terapi angina 
pektoris dan angina Prinzmetal. Namun, peran pemberian nitrat dalam 
memperbaiki gejala pasien PAD terbatas. Penelitian ini bertujuan mengkaji 
efektivitas pemberian nitrat eksogen dalam meningkatkan kadar NO plasma 
dan dalam memperbaiki gejala klinis pasien. Uji klinik pre-post prospektif 
yang melibatkan pasien PAD yang terdaftar di pencatatan vaskular di RSUP 
Dr. Sardjito dilakukan. Luaran utama penelitian ini adalah perubahan kadar 
NO plasma setelah pemberian nitrogliserin oral 2,5 mg satu kali sehari yang 
dinilai dalam jangka pendek (setelah 4 jam pemberian) dan jangka panjang 
(setelah 7 hari pemberian). Analisis varian dilanjutkan Bonferroni post test 
digunakan untuk uji hipotesis. Di antara 33 pasien yang mengikuti penelitian 
hingga selesai, tidak ditemukan efek samping negatif, hanya satu pasien 
hipotensi pada kunjungan pertama setelah 4 jam pemberian nitrogliserin. 
Kadar plasma NO meningkat setelah pemberikan nitrogliserin 4 jam dan 7 
hari, tetapi tidak bermakna (p > 0,05). Dapat disimpulkan, pemberian nitrat 
eksogen pada pasien PAD meningkatkatkan kadar NO plasma, meskipun 
tidak bermakna secara statistic.
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INTRODUCTION
Peripheral arterial disease (PAD) is a 
disease with reduction of blood flow in 
the limbs associated with atherosclerotic 
lesions which cause stenosis or occlusion 
of the arteries.1 The consequence of 
insufficient blood supply to the lower 
extremities is tissue ischemia leading to 
symptoms such as pain, pallor, pulseless, 
poikilothermia, paresthesia, paralysis 
and non-healing wounds or ulcers.2,3  In 
2010, more than 200 million people with 
PAD were reported globally, including 
54.8 million in Southeast Asia.4 Patients 
with PAD in Indonesia increased from 
1.7% in 1985 to 5.8% in 2014.5 According 
to the American Diabetes Association 
(ADA) in 2004,8 PAD is a major risk factor 
for lower limb amputation, especially in 
patients with diabetes mellitus.
In endothelial dysfunction, the 
formation of the substance that functions 
as a vasodilator called nitric oxide 
(NO) is disturbed.  NO is synthesized 
from L-arginine and is released from 
endothelial cells. It plays a role in the 
regulation of vascular tone and blood 
flow by relaxation of vascular smooth 
muscle cells by entering these cells 
and, activating guanylate cyclase that 
converts guanosine triphosphate (GTP) 
to cyclic guanosine monophosphate 
(GMP).9 NO also inhibits platelets 
aggregation, therefore the reduction 
of NO will facilitate the occurrence of 
stenosis, atherosclerosis, and thrombus.10 
Exogenous nitrate will be converted into 
NO at or near the plasma membranes of 
vascular smooth muscle cells. It will then 
give effect like physiological NO to repair 
endothelial damage, reduce arterial 
stiffness, and prevent thrombus while 
increasing the blood flow to hypoxic 
tissue.12 Nitrate is used as a treatment 
of angina pectoris through its systemic 
venous dilatation mechanism to reduce 
preload and has been given to patients 
with coronary artery spasm (Prinzmetal 
angina) for dilating coronary arterioles.11 
Nitrate can also be given for patients with 
PAD to maintain normal blood NO levels 
and reduce claudication. However, it 
has not been routinely performed there 
are and not enough data to support its 
effectiveness.12
The high prevalence of PAD causes 
the management of this disease to become 
challenging for clinicians. Nitrate is a 
simple form of nitric acid esters and 
nitrites from polyalcohol which are 
excreted through the liver. Its action 
mechanism influences blood NO levels.13 
Nitrate is easy to find, routinely used, 
and proven safe for patients with angina 
pectoris as one of the atherosclerosis 
manifestations. In addition, several 
studies reported administration of 
exogenous nitrates causes vasodilation 
of peripheral arteries and improves 
vascular function (Peak systolic velocity 
and 6 min walk test) in patients with 
PAD.14-16 This study aimed to evaluate 
the effectiveness of exogenous nitrates 
administration in increasing plasma 
NO levels and in improving vascular 
function in order to determine whether 
nitrate is a new effective treatment for 
patients with PAD.
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MATERIALS AND METHODS
Study design
A prospective pre-post clinical trial 
was conducted involving patients with 
PAD who were registered in the vascular 
registry at Dr. Sardjito General Hospital, 
Yogyakarta, Indonesia. This clinical trial 
was approved by the Medical and Health 
Research Ethics Committee (MHREC), 
Faculty of Medicine, Public Health and 
Nursing, Universitas Gadjah Mada/Dr. 
Sardjito General Hospital, Yogyakarta. 
Patients registration were conducted by 
a cardiologist and a researcher to record 
the data of patients with vascular disease 
from January 2016. The subjects were 
enrolled consecutively between March 
2017 until November 2018.
The inclusion criteria were: 1) 
patients who have been diagnosed 
with peripheral arterial disease based 
on criteria from the ESC 2011 or AHA 
Guidelines 2016; 2) > 18 years old; and 
3) agreed to participate in this research. 
The exclusion criteria were 1) patients 
with intolerance or contraindication 
to administration of nitrate; 2) patients 
with wounds in the lower extremities; 
3) patients with average systolic blood 
pressure <100 mmHg; and 4) patients 
with a history of sildenafil administration 
within one week of study.
Subjects who met the inclusion 
and exclusion criteria were recorded 
in a case report form for demographic, 
clinical data, and Doppler ultrasound 
examination results. Demographic data 
included age, gender and medicine being 
consumed by patients. Clinical data 
included risk factors for atherosclerosis 
(smoking, diabetes mellitus, family 
history, hypertension, and dyslipidemia). 
Other data information needed for 
research purposes was obtained from 
the medical records or from the history 
taking with patients. Sampling of data 
was conducted using non-probability 
sampling techniques.
Interventions and follow up
All patients under went the six-
minute walk test in the rehabilitation 
room of Dr. Sardjito General Hospital 
to determine the pain-free walking 
distance. Doppler ultrasound test was 
conducted to measure peak systolic 
velocity of inferior extremity artery 
with standard protocol. Blood sample 
was then collected for measurement of 
plasma NO levels. The patient was given 
2.5 mg oral nitroglycerin and the first 
follow-up was conducted after 4 h of 
administration. In the first follow up, the 
patients was evaluated for side effects of 
nitrate exposure and plasma NO levels. 
Patient was then given 2.5 mg oral 
nitroglycerin daily for 7 d. Second follow 
-up was performed in day 7 to evaluate 
the side effect of nitrate exposure, pain-
free walking distance by the six-minute 
walk test, peak systolic velocity with 
Doppler ultrasound and plasma NO 
levels (FIGURE1).
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FIGURE 1. CONSORT diagram
In the six-minute walk test, the pain 
was measured using a quantitative 
Visual Analog Scale (VAS) which was 
categorized as pain relief when subjects 
gave score 0. Doppler ultrasound 
examination was conducted with high-
frequency B-mode ultrasound (Philips 
1, Vivid 7 and Vivid S6) with 7-12MHz 
linear transducers. Neither observer nor 
operator was blind to the patient group.
Plasma NO levels were measured 
using colorimetry method (StressMarq 
Biosciences). Blood samples were taken 
and put into EDTA tubes for plasma and 
centrifuged for 15 min at 3000 rpm. 
Plasma was stored in the freezer with a 
minimum temperature -70 OC and before 
processing, the plasma was placed at 
room temperature for 30 min. Plasma 
sample was then filtered through 10,000 
MWCO spin filters to remove the protein. 
After that, the sample and reagents were 
mixed and incubated. The optical density 
was then read at λ 540-570 nm to find the 
total NO for all samples.
Outcomes
The primary outcome of this clinical 
trial was plasma NO levels after 4 h and 7 
d after exogenous nitrate administration. 
This study aimed to find if there is any 
significant increment of plasma NO 
levels after administration of exogenous 
355
Damarkusuma A, et al., Effect of nitrate administration...
nitrate. The secondary outcome included 
the safety of nitrate treatment in patients 
with PAD, pain-free walking distance by 
six-minute walk test and peak systolic 
velocity.
Statistical analysis
The data were analyzed by SPSS 
version 20.0. (IBM Corp., Armonk, NY) 
Basic characteristics were described 
as means ± standard deviation (SD) 
or total in number and percentage. 
Descriptive analysis of each variable 
was in numerical or interval for age, 
body mass index BMI, systolic blood 
pressure and in categorical or nominal 
for patient with hypertension, diabetes 
mellitus (DM), dyslipidemia, smoking, 
sex, and each interpretation of vascular 
function. For hypothesis testing,  analysis 
of variance continued with Bonferroni 
post test was applied due to this study 
took repeated measurements from each 
subject. Analysis was conducted between 
two groups (pre and post 4 h; pre and 
post 7 d). For numerical variables, the 
dependent t test was use for data with 
normal distribution or Mann-Whitney 
test was used if the data distribution was 
not normal. Number needed to treat and 
number needed to harm were analyzed 
to measure the effectivity and side effect.
RESULTS
Characteristics of patients
Thirty-six patients were enrolled in 
this study consisting of 26 (72.2%) male 
patients and 10 (27.8%) female patients. 
The average age of patients was 62.31±9.2 
y.o. with the youngest age of 31 y.o. and 
the oldest of 73 y.o. From the risk factors, 
28 patients (77.8%) had hypertension, 
16 (44.4%) had DM, 20 patients (55.6%) 
were active smoker, and 15 patients 
(41.7%) had dyslipidemia. The mean BMI 
was 24.51 ± 3.82 kg/m2. Three patients 
dropped out due to not attending the 
second follow-up so that a total of 33 
patients were involved in this study. 
No significant difference in the patients 
characteristics was observed (TABLE 1).
TABLE1. Basic characteristics of patients with PAD involving in this 
study
Variable Pre (n=36) Post1 (n=33) p
Sex
•	Male [n (%)] 26 (72.2) 24 (72.7) 0.963
•	Female [n (%)] 10 (27.8) 9 (27.3)
Age (year)2 62.31±9.19 62.63±9.46 0.968
Risk factor
•	Hypertension [n (%)] 28 (77.8) 26 (78.8) 0.919
•	Diabetes mellitus [n (%)] 16 (44.4) 16 (48.5) 0.737
•	Dyslipidemia [n (%)] 15 (41.7) 14 (42.4) 0.949
•	Smoker [n (%)] 20 (55.6) 18 (54.5) 0.933
BMI (kg/m2)2 24.51±3.82 24.66±3.89 0.667
Systolic BP (mmHg)2 140.4±17.50 141.51±17.42 0.979
Medication
•	Beta blocker [n (%)] 25 (26,3) 19 (57.6) 0.949
•	ACEi/ARB [n (%)] 22 (62.8) 27 (81.8) 0.677
•	Statin [n (%)] 36 (100) 33 (100) -
BMI: body mass index; BP: blood pressure; ARB: angiotensin receptor 
blocker; ACEi: angiotensin converting enzyme inhibitor; 1Post: from subjects 
who complete the second follow up; 2average ± standar dviation (with the 
assumption that data within normal distribution)
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Effect of nitrate administration on 
plasma NO levels
This study aimed to evaluate the 
effectiveness of the administration 
2.5 mg oral nitroglycerin daily or for 
7 d on plasma NO levels. Only one 
patient suffered from a hypotensive 
episode at the first follow-up or after 4 
h administration. The mean plasma NO 
level before nitroglycerin administration 
(pre group) was 10.5 ± 10.17 µM, whereas 
after 4 h administration (post group), it 
increased to 21.99 ± 32.38 µM. However, 
it was not significantly different (p> 
0.05). The mean plasma NO level post 7 d 
administration increased to 13.56 ±15.89 
μM. However, it was not significantly 
different (p=0.865). Furthermore, 
the mean plasma NO level post 7 d 
administration was lower compared to 
post 4 h administration, although it was 
also not significantly different.
The side effects or adverse effects 
were also evaluated using a 2 x 2 table 
analysis. One subject complained about 
having headaches at the first and second 
follow-up, but there were no other 
significantl side effects in other subjects. 
It was decided that the post 7 d group 
was chosen as a controls assuming 
complaints appeared related to acute 
exposure.
Effect of nitrate administration on 
vascular function
The six-minute walk test showed 
a significantl increase (p=0.001) of 
pain-free walking distance between 
the pre and post 7 d administration 
(281.97±121.26 m vs 262.56±123.34 m). 
In addition, the ratio of peak systolic 
velocity determined using Doppler 
ultrasound test significantly decreased 
after post 7 d administration compared 
to that in the  pre-administration. 
DISCUSSION
After 4h and 7d of nitrate 
administration, the plasma NO levels 
increased, even though it was not 
significantly different (p > 0.05). 
Whereas, the vascular function changed 
as demonstrated by the significantly 
increase in pain-free walking 
distance between the pre and post 7 d 
administration (p=0.002). Furthermore, 
the peak systolic velocity ratio was 
significantly decreased (p=0.002).
In this study, there were more male 
patients (72.2%) than female patients 
(27.7%). Previous study reported that 
gender is not associated with the 
incidence of PAD compared with other 
cardiovascular diseases.17 However, if 
claudication was used as a parameter 
as in Framingham, the incidence and 
prevalence of claudication are more 
common in men (7.1/1000) than in 
women (3.6/1000).18
In this study, average age of the 
patients was 62.31 ± 9.19 y.o.. The 
youngest subject was 31 y.o., while PAD 
rarely occurs at the age <40 y.o.17 The 
prevalence of PAD at the age <50 y.o. 
was under 5%, at the age of 65 y.o. it was 
around 10%, and at the age >80 y.o. > 
25%.2,19 In the Edinburgh Artery Study,4 
the incidence of PAD was mostly found 
in the age range of 55-74 y.o.
The risk factors of PAD in this study 
were hypertension (77.8%), smoking 
(55.6%), DM (44.4%) and dyslipidemia 
(41.7%). Hypertension was reported 
to increase the odds ratio (OR) for 
the incidence of PAD by 1.32 and in 
other study, the OR was 1.5-2.2.17,20 The 
Framingham study reported that the 
risk of claudication in the population 
will increase by 30% with systolic blood 
pressure (BP) >160 mmHg, and only 
systolic BP has a correlation with the 
incidence of PAD.2
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Smoking also increased the OR 
incidence of PAD. In the Rotterdam 
study,20 smoking increased the risk 
of PAD by 2.69 times compared with 
not smoking. Meanwhile, the Multi-
Ethnic Study of Atherosclerosis (MESA) 
reported,21 that smoking increases the 
risk of PAD up to 3.42 times. Diabetes 
mellitus is strongly associated with the 
incidence of PAD with an OR varying 
from 1.89 to 4.05. In addition, patients 
with PAD and DM have an amputation 
risk of about 50% compared to the PAD 
population without DM. This study also 
demonstrated that the risk of death 
increased three fold higher. Arteries 
affected in the DM population are also 
more distal than the knee.17
Dyslipidemia was only related with 
PAD in a univariate analysis. However, 
in a multivariate analysis, lipid variables 
were not an independent risk factor. 
Therefore, the role of lipids as an 
independent risk factor for PAD is not 
yet clear.2 High levels of low density 
lipoprotein-c reduce NO production in 
endothelial cells by regulation of caveolin 
proteins that inhibit interactions with 
eNOS.22
In this study, 2.5 mg oral nitroglycerin 
administration as exogenous nitrate 
increased plasma NO levels by 11.42 
µM after 4 h administration. Other 
studies reported that administration of 
organic nitrates such as beetroot juice 
increase plasma NO levels up to 2 µM. 
On the seventh day, plasma NO level 
increased 2.99 μM compared with before 
administration. This level was lower 
compared to after 4 h administration. 
Increased levels of NO in administration 
for less than 15 d were also found in 
transdermal nitrate studies up to 2.7 
μM.23 Acute increasing of nitrate maybe 
because its peak lasts between 2.5 to 4 
h.13 From this study, we found that there 
was no significant statistical Diffrence in 
the evidence (p = 0.865 and p = 0.643).
Nitrite oxide plays a role in 
regulation of vascular tone and 
blood flow by relaxation of vascular 
smooth muscle cells and also inhibits 
platelets aggregation. In this study, 
significant increase in pain-free walking 
distance between the pre and post 7 d 
administration was observed (p=0.001). 
Significantl decrease in the peak systolic 
velocity ratio (p=0.002) between the 
pre and post 7 d administration was 
also observed (p=0.002). These results 
demonstrated that administration of 
exogenous nitrated affected vascular 
function significantly by improving 
the flow through stenosis arteries and 
reduced the pain.
Some limitations of the study 
were reported. First, there were small 
sample sizes, with no placebo control 
group and no blinding that could cause 
high bias in the observation result. 
Second, in this study the exogenous 
nitrate administration was only done 
once whereas in another study, it was 
administered for longer duration. Third, 
the clinical parameter for the quality of 
pain evaluation used a six-minute walk 
test which was subjective because the 
pain was only analyzed from history 
taking. Further studies are needed 
using larger samples, with controls 
blinding and longer duration of nitrate 
administration to avoid the potential for 
bias and confirm the findings.
CONCLUSIONS
In conclusion, administration of 
exogenous nitrates on patients with PAD 
for 7 days improves the vascular function 
as demonstrated by the significant 
increase of pain-free walking distance 
and the decrease of peak systolic velocity 
ratio. Moreover, the administration of 
exogenous nitrates also increases plasma 
NO level, although the result were not 
statistically significant.
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